Completeness of tuberculosis case notifications in Germany in 2013–2017: first results of an inventory study

BMC Infectious Diseases

Table 1 Adjustments to the DDD_PZA and PZA treatment length based on notified patients’ characteristics

Adjustment to	Notified variable	Value of the notified variable	Adjustment
DDD_PZA*	Age group	0–4	500 mg
		5–10	750 mg
		11–14	1250 mg
		> 14	1750 mg
Treatment length	Resistance against	Isoniazid + Ethambutol	10.5 months (average of the recommended 9 to 12 months)
		Isoniazid + Rifampicin**	18 months
		PZA	0 months
	Hospitalization	Hospital admission and discharge dates	Recommended PZA treatment time (60 days) minus number of days of hospitalization falling within PZA treatment time
	Hospitalization	Hospitalization status = “yes”	Recommended PZA treatment time (60 days) minus average number of days of hospitalization*** falling within PZA treatment time
	Death during treatment	Date of death	Recommended PZA treatment time (60 days) minus number of days between date of death and expected treatment end time

*The adjustments to DDD_PZA were based on patient’s age since weight is not a notifiable variable. The dosage assumed for age groups was based on the recommendations of the medication producer Riemser Arzneimittel AG, Germany, which supplied the majority of PZA in Germany from 2013-2017 (according to the PZA pharmacy data)
**Multidrug-resistant TB (MDR-TB)
***Calculated based on hospitalized TB patients from the corresponding year

ISSN: 1471-2334